Literature DB >> 24837467

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Eric Lippert1, Olivier Mansier2, Marina Migeon3, Barbara Denys4, Asa Nilsson5, Carolina Rosmond5, Laurence Lodé6, Valérie Ugo7, Axelle Lascaux8, Beatriz Bellosillo9, Joaquin Martinez-Lopez10, Dina Naguib11, Nathalie Gachard12, Nicolas Maroc13, Sylvie Hermouet14.   

Abstract

Entities:  

Keywords:  JAK2V617F; low allele burden; myeloproliferative neoplasm

Mesh:

Substances:

Year:  2014        PMID: 24837467      PMCID: PMC4077092          DOI: 10.3324/haematol.2014.107656

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Is the JAK2(V617F) mutation detectable in healthy volunteers?

Authors:  Christophe Martinaud; Patrick Brisou; Marie-Joelle Mozziconacci
Journal:  Am J Hematol       Date:  2010-04       Impact factor: 10.047

2.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Authors:  Eric Lippert; Marjorie Boissinot; Robert Kralovics; François Girodon; Irène Dobo; Vincent Praloran; Nathalie Boiret-Dupré; Radek C Skoda; Sylvie Hermouet
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Thomas Stauffer Larsen; Jacob Haaber Christensen; Hans Carl Hasselbalch; Niels Pallisgaard
Journal:  Br J Haematol       Date:  2007-03       Impact factor: 6.998

4.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

5.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.

Authors:  Anthony J Bench; Helen E White; Letizia Foroni; Anna L Godfrey; Gareth Gerrard; Susanna Akiki; Abida Awan; Ian Carter; Andrea Goday-Fernandez; Stephen E Langabeer; Tim Clench; Jordan Clark; Paul A Evans; David Grimwade; Anna Schuh; Mary F McMullin; Anthony R Green; Claire N Harrison; Nicholas C P Cross
Journal:  Br J Haematol       Date:  2012-10-11       Impact factor: 6.998

8.  Detectable clonal mosaicism from birth to old age and its relationship to cancer.

Authors:  Cathy C Laurie; Cecelia A Laurie; Kenneth Rice; Kimberly F Doheny; Leila R Zelnick; Caitlin P McHugh; Hua Ling; Kurt N Hetrick; Elizabeth W Pugh; Chris Amos; Qingyi Wei; Li-e Wang; Jeffrey E Lee; Kathleen C Barnes; Nadia N Hansel; Rasika Mathias; Denise Daley; Terri H Beaty; Alan F Scott; Ingo Ruczinski; Rob B Scharpf; Laura J Bierut; Sarah M Hartz; Maria Teresa Landi; Neal D Freedman; Lynn R Goldin; David Ginsburg; Jun Li; Karl C Desch; Sara S Strom; William J Blot; Lisa B Signorello; Sue A Ingles; Stephen J Chanock; Sonja I Berndt; Loic Le Marchand; Brian E Henderson; Kristine R Monroe; John A Heit; Mariza de Andrade; Sebastian M Armasu; Cynthia Regnier; William L Lowe; M Geoffrey Hayes; Mary L Marazita; Eleanor Feingold; Jeffrey C Murray; Mads Melbye; Bjarke Feenstra; Jae H Kang; Janey L Wiggs; Gail P Jarvik; Andrew N McDavid; Venkatraman E Seshan; Daniel B Mirel; Andrew Crenshaw; Nataliya Sharopova; Anastasia Wise; Jess Shen; David R Crosslin; David M Levine; Xiuwen Zheng; Jenna I Udren; Siiri Bennett; Sarah C Nelson; Stephanie M Gogarten; Matthew P Conomos; Patrick Heagerty; Teri Manolio; Louis R Pasquale; Christopher A Haiman; Neil Caporaso; Bruce S Weir
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

9.  Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Authors:  J V Jovanovic; A Ivey; A M Vannucchi; E Lippert; E Oppliger Leibundgut; B Cassinat; N Pallisgaard; N Maroc; S Hermouet; G Nickless; P Guglielmelli; B A van der Reijden; J H Jansen; T Alpermann; S Schnittger; A Bench; K Tobal; B Wilkins; K Cuthill; D McLornan; K Yeoman; S Akiki; J Bryon; S Jeffries; A Jones; M J Percy; S Schwemmers; A Gruender; T W Kelley; S Reading; A Pancrazzi; M F McMullin; H L Pahl; N C P Cross; C N Harrison; J T Prchal; C Chomienne; J J Kiladjian; T Barbui; D Grimwade
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

10.  Detectable clonal mosaicism and its relationship to aging and cancer.

Authors:  Kevin B Jacobs; Meredith Yeager; Weiyin Zhou; Sholom Wacholder; Zhaoming Wang; Benjamin Rodriguez-Santiago; Amy Hutchinson; Xiang Deng; Chenwei Liu; Marie-Josephe Horner; Michael Cullen; Caroline G Epstein; Laurie Burdett; Michael C Dean; Nilanjan Chatterjee; Joshua Sampson; Charles C Chung; Joseph Kovaks; Susan M Gapstur; Victoria L Stevens; Lauren T Teras; Mia M Gaudet; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Philip R Taylor; Neal D Freedman; Christian C Abnet; Alisa M Goldstein; Nan Hu; Kai Yu; Jian-Min Yuan; Linda Liao; Ti Ding; You-Lin Qiao; Yu-Tang Gao; Woon-Puay Koh; Yong-Bing Xiang; Ze-Zhong Tang; Jin-Hu Fan; Melinda C Aldrich; Christopher Amos; William J Blot; Cathryn H Bock; Elizabeth M Gillanders; Curtis C Harris; Christopher A Haiman; Brian E Henderson; Laurence N Kolonel; Loic Le Marchand; Lorna H McNeill; Benjamin A Rybicki; Ann G Schwartz; Lisa B Signorello; Margaret R Spitz; John K Wiencke; Margaret Wrensch; Xifeng Wu; Krista A Zanetti; Regina G Ziegler; Jonine D Figueroa; Montserrat Garcia-Closas; Nuria Malats; Gaelle Marenne; Ludmila Prokunina-Olsson; Dalsu Baris; Molly Schwenn; Alison Johnson; Maria Teresa Landi; Lynn Goldin; Dario Consonni; Pier Alberto Bertazzi; Melissa Rotunno; Preetha Rajaraman; Ulrika Andersson; Laura E Beane Freeman; Christine D Berg; Julie E Buring; Mary A Butler; Tania Carreon; Maria Feychting; Anders Ahlbom; J Michael Gaziano; Graham G Giles; Goran Hallmans; Susan E Hankinson; Patricia Hartge; Roger Henriksson; Peter D Inskip; Christoffer Johansen; Annelie Landgren; Roberta McKean-Cowdin; Dominique S Michaud; Beatrice S Melin; Ulrike Peters; Avima M Ruder; Howard D Sesso; Gianluca Severi; Xiao-Ou Shu; Kala Visvanathan; Emily White; Alicja Wolk; Anne Zeleniuch-Jacquotte; Wei Zheng; Debra T Silverman; Manolis Kogevinas; Juan R Gonzalez; Olaya Villa; Donghui Li; Eric J Duell; Harvey A Risch; Sara H Olson; Charles Kooperberg; Brian M Wolpin; Li Jiao; Manal Hassan; William Wheeler; Alan A Arslan; H Bas Bueno-de-Mesquita; Charles S Fuchs; Steven Gallinger; Myron D Gross; Elizabeth A Holly; Alison P Klein; Andrea LaCroix; Margaret T Mandelson; Gloria Petersen; Marie-Christine Boutron-Ruault; Paige M Bracci; Federico Canzian; Kenneth Chang; Michelle Cotterchio; Edward L Giovannucci; Michael Goggins; Judith A Hoffman Bolton; Mazda Jenab; Kay-Tee Khaw; Vittorio Krogh; Robert C Kurtz; Robert R McWilliams; Julie B Mendelsohn; Kari G Rabe; Elio Riboli; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Joanne W Elena; Herbert Yu; Laufey Amundadottir; Rachael Z Stolzenberg-Solomon; Peter Kraft; Fredrick Schumacher; Daniel Stram; Sharon A Savage; Lisa Mirabello; Irene L Andrulis; Jay S Wunder; Ana Patiño García; Luis Sierrasesúmaga; Donald A Barkauskas; Richard G Gorlick; Mark Purdue; Wong-Ho Chow; Lee E Moore; Kendra L Schwartz; Faith G Davis; Ann W Hsing; Sonja I Berndt; Amanda Black; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Beata Peplonska; Katherine A McGlynn; Michael B Cook; Barry I Graubard; Christian P Kratz; Mark H Greene; Ralph L Erickson; David J Hunter; Gilles Thomas; Robert N Hoover; Francisco X Real; Joseph F Fraumeni; Neil E Caporaso; Margaret Tucker; Nathaniel Rothman; Luis A Pérez-Jurado; Stephen J Chanock
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more
  7 in total

1.  The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.

Authors:  Matthew Goodyer; Stephen E Langabeer; Karl Haslam; Karen Murphy
Journal:  Pathol Oncol Res       Date:  2015-10-08       Impact factor: 3.201

Review 2.  The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Authors:  Marjorie Boissinot; Mathias Vilaine; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2014-08-12       Impact factor: 6.639

3.  Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation.

Authors:  Soji Morishita; Kochi Takahashi; Marito Araki; Yumi Hironaka; Yoshitaka Sunami; Yoko Edahiro; Miyuki Tsutsui; Akimichi Ohsaka; Satoshi Tsuneda; Norio Komatsu
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

4.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

5.  Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Authors:  Margherita Perricone; Francesca Palandri; Emanuela Ottaviani; Mario Angelini; Laura Bagli; Enrica Bellesia; Meris Donati; Donato Gemmati; Patrizia Zucchini; Stefania Mancini; Valentina Marchica; Serena Trubini; Giovanna De Matteis; Silvia Di Zacomo; Mosè Favarato; Annamaria Fioroni; Caterina Bolzonella; Giorgia Maccari; Filippo Navaglia; Daniela Gatti; Luisa Toffolatti; Linda Orlandi; Vèronique Laloux; Marco Manfrini; Piero Galieni; Barbara Giannini; Alessia Tieghi; Sara Barulli; Maria Luisa Serino; Monica Maccaferri; Anna Rita Scortechini; Nicola Giuliani; Daniele Vallisa; Massimiliano Bonifacio; Patrizia Accorsi; Cristina Salbe; Vinicio Fazio; Milena Gusella; Eleonora Toffoletti; Marzia Salvucci; Mirija Svaldi; Filippo Gherlinzoni; Francesca Cassavia; Francesco Orsini; Giovanni Martinelli
Journal:  Oncotarget       Date:  2017-05-16

6.  A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.

Authors:  Dorota Link-Lenczowska; Niels Pallisgaard; Sabrina Cordua; Magdalena Zawada; Sylwia Czekalska; Dorota Krochmalczyk; Zuzanna Kanduła; Tomasz Sacha
Journal:  Ann Hematol       Date:  2018-07-28       Impact factor: 3.673

7.  Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Authors:  Marte Karen Brattås; Kyrre Lilleeng; Randi Hovland; Ingvild Jenssen Lægreid; Marta Vorland; Friedemann Leh; Øystein Bruserud; Bjørn Tore Gjertsen; Håkon Reikvam
Journal:  Biomark Res       Date:  2018-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.